A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Phase 2 Completed 559 enrolled Astellas Pharma Inc

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is to investigate the efficacy, safety, and plasma concentration change of ASP0456 in patients with constipation-predominant irritable bowel syndrome.

Timeline

Start: 2012-08-10
Primary completion: 2013-12-07
Completion: 2013-12-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Linaclotide	Peptide	—	Oral

A Study to Evaluate the Effect of ASP0456 in Patients With Constipation Predominant Irritable Bowel Syndrome

Summary

Timeline

Drugs

Indications